Urologic Cancers News
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
Nadofaragene firadenovec, a novel gene-mediated therapy, achieved a 53.4% complete response rate in patients with high-grade carcinoma in situ unresponsive to bacillus Calmette-Guérin, phase 3 trial results show.
Combination neoadjuvant therapy with nivolumab and gemcitabine-cisplatin in patients with muscle-invasive bladder cancer resulted in significant pathologic downstaging at radical cystectomy, with manageable toxicities.
Survival of patients with intermediate-risk metastatic renal cell carcinoma varied according to the number of IMDC or MSKCC risk factors.
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
In a study, cytoreductive nephrectomy was not independently associated with improved survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.
Sterile pyuria may be a marker of inflammation, which is known to influence carcinogenesis.
In a study of patients with upper tract urothelial carcinoma, variant vs conventional histology predicted worse survival.
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
Higher birth weight and overweight in childhood found to predict an increased risk of renal cell carcinoma in adulthood, a large Danish study found.
Intravesical incision of the bladder cuff may be superior to other distal ureteral management techniques, according to investigators.
The cancer field is not immune to the challenges of out-of-network and surprise billing.
More studies needed to understand role of MMR deficiency as biomarker of immune response.